A novel tocopherol derivative suppresses obesity in high-fat diet-induced obese mice

Area of Science:

• Biochemistry
• Pharmacology
• Metabolic Diseases

Background:

• Lipid accumulation is central to obesity pathogenesis, but effective drug targets remain limited.
• Existing compounds like α-tocopheryl succinate (TS) show efficacy but also cytotoxicity.
• Previous attempts with α-tocopheryl adipate (Tadi) were hindered by stability concerns for oral administration.

Purpose of the Study:

• To synthesize and evaluate deoxo α-tocopheryl adipate (dTadi), a more stable ether analog of Tadi, as a potential anti-obesity agent.
• To assess the efficacy and safety of dTadi in vitro and in vivo models of obesity.
• To investigate the underlying mechanisms of dTadi's anti-obesity effects.

Main Methods:

• Synthesis of dTadi, an ether analog of Tadi, replacing the ester bond with a more stable ether bond.
• In vitro assessment of dTadi's effect on lipid accumulation and cytotoxicity in relevant cell models.
• In vivo studies involving high-fat diet-fed mice to evaluate body weight, food intake, metabolic parameters, and fat mass reduction.
• Analysis of liver lipid content, adipose tissue morphology, and key metabolic markers including UCP1 and fatty acid oxidation.

Main Results:

• dTadi demonstrated significant inhibition of lipid accumulation in vitro without inducing cytotoxicity.
• Oral administration of dTadi dose-dependently suppressed body weight gain (13-20%) in mice on a high-fat diet, without affecting food intake.
• dTadi treatment led to reduced blood glucose, serum triglycerides, decreased visceral fat mass, and attenuated liver steatosis.
• Mechanism studies indicated increased glycerol release, UCP1 expression, and fatty acid β-oxidation.

Conclusions:

• dTadi is a chemically stable α-tocopherol derivative with potent anti-obesity effects.
• dTadi effectively reduces body weight and improves metabolic parameters in vivo, offering a promising new therapeutic strategy for obesity.
• The compound exhibits a favorable safety profile, supporting its potential as an oral anti-obesity medication.